CYP51A1 and parasitic infectious disease: Similar results—supression of parasitemia, no spontaneous relapse after treatment withdrawal and parasite reactivation after immunossupression—were also achieved by other research groups using CYP51 inhibitors based on different molecular scaffolds [41,46,55].